MTAP and cancer: On the basis of preclinical evidence showing tumor regression in MTAP-deleted xenograft models with PRMT5 inhibition, a phase 1/2 study is currently recruiting patients with locally advanced or metastatic MTAP-deleted mesothelioma to receive TNG908, a selective PRMT5 inhibitor in MTAP-null cancers (NCT05275478) [55].